The agreement emerged from the Blue-Sky Visioning and Think Tank Workshop held in Johannesburg from November 25 to 27, 2025.
Results showed that the injectable regimen performed just as well as the daily oral dolutegravir-based therapy (TLD) but helped reduce the burden of daily medication.